Adeno-Associated Virus Capsid-Promoter Interactions in the Brain Translate from Rat to the Nonhuman Primate

Abstract

Recently, we established an adeno-associated virus (AAV9) capsid-promoter interaction that directly determined cellspecific gene expression across two synthetic promoters, Cbh and CBA, in the rat striatum. These studies not only expand this capsid-promoter interaction to include another promoter in the rat striatum but also establish AAV capsid-promoter interactions in the nonhuman primate brain. When AAV serotype 9 (AAV9) vectors were injected into the rat striatum, the minimal synthetic promoter JetI drove green fluorescent protein (GFP) gene expression predominantly in oligodendrocytes. However, similar to our previous findings, the insertion of six alanines into VP1/VP2 of the AAV9 capsid (AAV9AU) significantly shifted JetI-driven GFP gene expression to neurons. In addition, previous retrograde tracing studies in the nonhuman primate brain also revealed the existence of a capsid-promoter interaction. When rAAV2-Retro vectors were infused into the frontal eye field (FEF) of rhesus macaques, local gene expression was prominent using either the hybrid chicken beta actin (CAG) or human synapsin (hSyn) promoters. However, only the CAG promoter, not the hSyn promoter, led to gene expression in the ipsilateral claustrum and contralateral FEF. Conversely, infusion of rAAV2-retro-hSyn vectors, but not rAAV2-retro-CAG, into the macaque superior colliculus led to differential and selective retrograde gene expression in cerebellotectal afferent cells. Clearly, this differential promoter/capsid expression profile could not be attributed to promoter inactivation from retrograde transport of the rAAV2-Retro vector. In summary, we document the potential for AAV capsid/promoter interactions to impact cell-specific gene expression across species, experimental manipulations, and engineered capsids, independent of capsid permissivity.

Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice

“…This may be due to the viral subtype used (AAV2 versus AAV9), animal species (canine versus murine), or timing of treatment (3 months of age versus P1), and it is unclear what parameters are necessary for successful retinal expression via CSF delivery, including interactions between capsid and promoter. 39 Importantly, given the differences between visual processes of rodents and humans, our study will need to be validated in animal models that are more reliant on the thalamus for visual processing.…”

Genetically engineered microglia-like cells have therapeutic potential for neurodegenerative disease

“…Furthermore, previous work has demonstrated that AAV administration into the parenchyma leads to extremely high levels of transgene expression close to the injection site but a vastly lower expression level in distal brain regions 43,57 . Importantly, the cell type that expresses the therapeutic protein will depend on the AAV capsid and promoter used 58 . Conversely, we showed here that the tiling behavior of MLCs expands the reach of HSPC-derived cells to the whole brain, resulting in an even and widespread (which was not certified by peer review) is the author/funder.…”

Adeno-Associated Viral Vectors as Versatile Tools for Parkinson’s Research, Both for Disease Modeling Purposes and for Therapeutic Uses

“…Moreover, interactions between AAV capsids and promoters driving cell type transduction regardless of virus permissivity have been recently reported in both rodent and NHPs, and these interactions include widely-used promoters such as CBA and JetI [19,20].…”